imipramine has been researched along with nefazodone in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.70) | 18.7374 |
| 1990's | 18 (48.65) | 18.2507 |
| 2000's | 6 (16.22) | 29.6817 |
| 2010's | 12 (32.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Boyer, WF; D'Amico, MF; Feighner, JP; Fowler, RC; Pambakian, R | 1 |
| Anton, SF; Revicki, DA | 1 |
| Preskorn, SH | 1 |
| Anton, SF; Fawcett, J; Marcus, RN; O'Brien, K; Schwiderski, U | 1 |
| Marcus, RN; Rickels, K; Roberts, DL; Robinson, DS; Schweizer, E | 1 |
| van Laar, MW; van Willigenburg, AP; Volkerts, ER | 1 |
| Anton, SF; Archibald, DG; English, PA; Kensler, TT; Roberts, DL; Robinson, DS | 1 |
| Clary, C; Fox, I; Rickels, K; Schweizer, E; Weise, C | 1 |
| Ecker, JA; Elie, R; Faludi, G; Fontaine, R; Kaplita, S; Kensler, TT; Ontiveros, A; Roberts, DL | 1 |
| Frewer, LJ; Lader, M | 1 |
| Zajecka, JM | 1 |
| Cohn, CK; Ieni, JR; O'Brien, K; Roberts, DL; Robinson, DS; Schwiderski, UE | 1 |
| Marcus, RN; Mendels, J | 1 |
| Montgomery, SA | 1 |
| Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC | 1 |
| Brown, RE; Clark, M; Montgomery, SA | 1 |
| Brown, RE; Culpepper, L; Gonzales, J; Hales, RE; Keller, MB; Revicki, DA | 1 |
| Anton, SF; Bakish, D; Brown, RE; Feeny, D; Palmer, W; Revicki, DA; Rosser, WW | 1 |
| Bikoff, J; Ginsberg, DL; Sussman, N | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
7 review(s) available for imipramine and nefazodone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; Piperazines; Placebos; Psychomotor Agitation; Randomized Controlled Trials as Topic; Triazoles | 1995 |
Efficacy in long-term treatment of depression.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Humans; Imipramine; Long-Term Care; Piperazines; Placebos; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Treatment Outcome; Triazoles | 1996 |
The safety profile of nefazodone.
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Depressive Disorder; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Imipramine; Male; Middle Aged; Mixed Function Oxygenases; Piperazines; Placebos; Sexual Dysfunctions, Psychological; Treatment Outcome; Triazoles; Weight Gain | 1996 |
Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Body Weight; Controlled Clinical Trials as Topic; Depressive Disorder; Female; Humans; Imipramine; Male; Piperazines; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome; Triazoles; Weight Gain | 2001 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
11 trial(s) available for imipramine and nefazodone
| Article | Year |
|---|---|
A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression.
Topics: Adult; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; Piperazines; Randomized Controlled Trials as Topic; Triazoles | 1989 |
Nefazodone: aspects of efficacy.
Topics: Ambulatory Care; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Humans; Imipramine; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Survival Analysis; Treatment Outcome; Triazoles | 1995 |
Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects.
Topics: Adult; Aged; Aging; Antidepressive Agents; Automobile Driving; Cognition; Double-Blind Method; Humans; Imipramine; Multivariate Analysis; Piperazines; Psychomotor Performance; Reaction Time; Reference Values; Sleep; Triazoles | 1995 |
Long-term treatment of depression with nefazodone.
Topics: Antidepressive Agents; Chronic Disease; Depressive Disorder; Double-Blind Method; Humans; Imipramine; Piperazines; Triazoles | 1994 |
Nefazodone and imipramine in major depression: a placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Middle Aged; Personality Inventory; Piperazines; Triazoles | 1994 |
A double-blind comparison of nefazodone, imipramine, and placebo in major depression.
Topics: Adult; Aged; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Middle Aged; Patient Compliance; Patient Dropouts; Piperazines; Placebos; Psychiatric Status Rating Scales; Recurrence; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Triazoles | 1994 |
The effects of nefazodone, imipramine and placebo, alone and combined with alcohol, in normal subjects.
Topics: Adolescent; Adult; Antidepressive Agents; Body Temperature; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Electroencephalography; Ethanol; Female; Hemodynamics; Humans; Imipramine; Male; Memory; Piperazines; Psychomotor Performance; Reference Values; Triazoles | 1993 |
The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Community Mental Health Services; Comorbidity; Depressive Disorder; Drug Administration Schedule; Family Practice; Female; Humans; Imipramine; Male; Middle Aged; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Retrospective Studies; Treatment Outcome; Triazoles | 1996 |
Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 1996 |
Nefazodone in the treatment of severe, melancholic, and recurrent depression.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Middle Aged; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Recurrence; Severity of Illness Index; Treatment Outcome; Triazoles | 1996 |
Economic analysis of treating depression with nefazodone v. imipramine.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Depressive Disorder; Double-Blind Method; England; Humans; Imipramine; Models, Economic; Piperazines; Recurrence; Treatment Outcome; Triazoles; Wales | 1996 |
19 other study(ies) available for imipramine and nefazodone
| Article | Year |
|---|---|
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
Topics: Antidepressive Agents; Cost-Benefit Analysis; Decision Support Techniques; Economics, Pharmaceutical; Fluoxetine; Follow-Up Studies; Humans; Imipramine; Models, Economic; Piperazines; Treatment Outcome; Triazoles | 1995 |
New perspectives in the management of depression. Symposium highlights from ECNP, Venice, September 1995.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder; Humans; Imipramine; Piperazines; Triazoles | 1996 |
Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Depressive Disorder; Drug Costs; Fluoxetine; Health Care Costs; Health Policy; Health Services; Humans; Imipramine; Managed Care Programs; Patient Compliance; Piperazines; Probability; Quality-Adjusted Life Years; Treatment Failure; Treatment Outcome; Triazoles | 1997 |
Modelling the cost effectiveness of antidepressant treatment in primary care.
Topics: Antidepressive Agents; Decision Support Techniques; Depressive Disorder; Female; Fluoxetine; Humans; Imipramine; Markov Chains; Models, Economic; Piperazines; Primary Health Care; Quality-Adjusted Life Years; Sensitivity and Specificity; Triazoles | 1995 |